The study results suggested that glucagon as an antagonistic hormone might beneficially impact cardiovascular outcomes in people with T2D treated with insulin (65), an hypothesis that needs of course be investigated in randomized controlled trials. The gene discussed is GCG; the disease is type 2 diabetes mellitus.